Channels - Cutaneous Manifestations in Psoriatic Arthritis: Phenotypes, Clinical Burden, and Therapeutic Implications :: FRELIP Discovery

Similar Items: Cutaneous Manifestations in Psoriatic Arthritis: Phenotypes, Clinical Burden, and Therapeutic Implications

Quick Look
Prescription Patterns in Psoriatic Arthritis: Insights from a Sex-Based Perspective
Quick Look
Hepatic fibrosis in patients diagnosed with rheumatoid arthritis and psoriatic arthritis receiving methotrexate: A cross‐sectional analysis using transient elastography
Quick Look
Ten-year longitudinal assessment of entheseal ultrasound in psoriasis: limited discriminatory capacity for psoriatic arthritis
Quick Look
Treatment Patterns and Outcomes of Acthar Gel in Ankylosing Spondylitis and Psoriatic Arthritis: A Physician-Reported Chart Review
Quick Look
Expert Opinion Report on the Challenges in the Management of Psoriatic Arthritis in United Arab Emirates: A Focus on Interleukin-17 Inhibitors
Quick Look
Correction: Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
Quick Look
Real-world experience with Janus kinase inhibitors in rheumatoid and psoriatic arthritis: retention and discontinuation factors in a UK six-centre cohort
Quick Look
Decision on Optimal Combinatorial Therapies in Immune-mediated inflammatory diseases using Systems approaches (DocTIS): protocol for a single-arm, adaptive basket trial in rheumatoid and psoriatic arthritis
Quick Look
Clinical features and comorbidity patterns in early and very early rheumatoid arthritis: Insights from a China nationwide survey
Quick Look
Efficacy/Effectiveness, Safety and Treatment Persistence of Filgotinib in Rheumatoid Arthritis: A Narrative Review of Clinical Trials and Real-World Evidence
Quick Look
The association between bariatric surgery and incident rheumatoid arthritis
Quick Look
Herpes Zoster Risk in Rheumatoid Arthritis Patients on Janus Kinase Inhibitors: A 17-Year Experience from Rheumatoid Arthritis Saudi Database (RASD)
Quick Look
Real-World Upadacitinib Persistence and Clinical Outcomes Among Canadian Patients with Inflammatory Arthritis from a Patient Support Program: The UPRAISE Study
Quick Look
Clinical and Economic Burden Among People with Knee Osteoarthritis and Obesity in the United States: A Retrospective Analysis
Quick Look
Anti-NXP2 antibody-positive dermatomyositis presenting as systemic capillary leak syndrome with cutaneous and gastrointestinal ulcers
Quick Look
Pericarditis as the Initial Manifestation of Antisynthetase Syndrome: A Case Report
Quick Look
Giant cell arteritis–associated temporomandibular joint arthritis confirmed by imaging
Quick Look
Janus kinase inhibitor and rituximab in rheumatoid arthritis: is it a safe combination?
Quick Look
The prevalence of interstitial lung disease in rheumatoid arthritis: a systematic review
Quick Look
Correction to “Usefulness of Sarilumab in Patients with Rheumatoid Arthritis after Regression of Lymphoproliferative Disorders”
Quick Look
Variation in the feasibility and acceptability of electronic patient-reported outcome measures in patients with inflammatory arthritis
Quick Look
Characterizing Adherence to a Mobile Health App for Patient-Reported Outcomes in Rheumatoid Arthritis
Quick Look
Exploring Antifibrotic Strategies for Interstitial Lung Disease in Rheumatoid Arthritis: A Narrative Review
Quick Look
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)